Hashimoto’s thyroiditis is usually treated like a numbers problem: TSH normalizes, levothyroxine is “working,” end of story. But many patients live in a different reality: persistent fatigue, poor sleep, brain fog, low mood, pain, and a feeling of being drained even when labs look fine.

In this Deep Dive, Dr. Mike breaks down a study that tested photobiomodulation (PBM) applied over the thyroid region as an adjunct to standard treatment. The key focus wasn’t just lab values — it was how people actually felt: fatigue severity, fatigue impact, sleep quality, daytime sleepiness, anxiety, depression, and pain. Both sham and active groups improved (placebo and therapeutic attention are real), but the active PBM group improved more across every major symptom category, suggesting a broader shift in underlying physiology — likely involving mitochondrial function, oxidative stress, and inflammatory signaling.

Bottom line: this isn’t “light replaces medicine.” It’s a serious look at what happens when replacement therapy corrects a piece of the picture, but the energetic terrain still needs support.

(Educational content only, not medical advice.)

Article Discussed in Episode:

The effect of photobiomodulation therapy on fatigue and behavioural status in patients with Hashimoto’s thyroiditis

Key Quotes From Dr. Mike:

"This paper doesn’t frame Hashimoto’s only as a hormone problem — it points to inflammation, oxidative stress, and mitochondrial dysfunction.”

“The active photobiomodulation group improved more; across every major symptom category measured.”

“When you see energy, mood, sleep, and pain shift together, you’re not looking at a narrow effect — you’re looking at a deeper physiological influence.”

“Hormone replacement may correct part of the picture, but not always restore cellular energy dynamics.”

“Healing isn’t just bringing a number into range. Healing is restoring function.”

Key Points

Hashimoto’s isn’t only a hormone story — persistent symptoms may reflect inflammation, oxidative stress, and mitochondrial strain even when labs normalize.
Study design: PBM + levothyroxine vs sham + levothyroxine, applied over the thyroid region 2x/week for 3 weeks.
Outcomes prioritized real life symptoms: fatigue (severity + impact), sleep quality, daytime sleepiness, anxiety, depression, pain.
Both groups improved, reinforcing the role of expectation/attention/placebo.
Active PBM improved more across all main symptom categories measured.
Mechanistic framing: PBM may support mitochondrial respiration/ATP, modulate ROS, reduce oxidative stress, and influence cytokines/inflammation.
Improvements in sleep + mood matter because they often drive the entire “fatigue spiral.”
This is not a cure study and not definitive for long-term outcomes, but it’s clinically meaningful because it targets what patients actually report.
Core message: numbers can improve while function lags — and function is the point.

Episode timeline

0:19 – 0:55 Intro + the core problem: Hashimoto’s patients still feel bad even with “better labs”
0:55 – 2:16 Why standard care can fall short: symptoms persist despite levothyroxine normalization
2:16 – 3:17 BioLight lens: inflammation, oxidative stress, mitochondrial dysfunction as the “missing layer”
3:17 – 4:36 Study setup: PBM over thyroid region, randomized groups, symptom-focused outcomes
4:41 – 5:33 Results: both groups improved, but active PBM improved more across the board
5:55 – 7:50 Mechanism discussion: mitochondria/ATP, ROS signaling, oxidative stress, immune modulation
8:19 – 10:14 Mood + sleep: why improvements here suggest systemic regulation, not a narrow effect
10:16 – 11:14 Grounding + limitations: not a huge trial, sham improved, don’t overclaim
11:14 – 13:29 Practical meaning: restoring function, resilience, and “vitality outcomes”

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

Stay up-to-date on social media:

Dr. Mike Belkowski:

BioLight: